{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-007063","form_type":"8-K","ticker":"XLO","cik":"0001840233","company_name":"Xilio Therapeutics, Inc.","filed_at":"2026-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.482179+00:00","generated_at":"2026-05-16T11:15:07.914705+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Xilio reports $137.5M cash, appoints chair, gets $35.8M from warrants","bullets":["Cash $137.5M at Dec 31, 2025, including $35.8M from Series B warrants; runway into Q2 2027.","Full exercise of Series B warrants by Coastlands Capital, Frazier Life Sciences, and Gilead.","Achieved milestone for masked antibody program under AbbVie; nominated CLDN18.2 T cell engager candidate.","Appointed Sara Bonstein as board chair, succeeding Paul Clancy who retired Jan 6, 2026.","Pipeline milestones: IND for XTX501 mid-2026, initial Phase 1 data H2 2027, STEAP1 candidate H1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-007063","json":"https://secwatch.observer/filing/0001193125-26-007063.json","markdown":"https://secwatch.observer/filing/0001193125-26-007063.md","text":"https://secwatch.observer/filing/0001193125-26-007063.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526007063/0001193125-26-007063-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526007063/xlo-20260108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:15:07.914705+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}